Vitamin D trial for COVID-19 – using their patented slow-release form

OPKO patented a slow release form of Vitamin D to treat Chronic Kidney Disease in 2014

It is extremely expensive, and now the company hopes to show that it fight COVID-19

Standard, far lower cost, over-the-counter vitamin D would be better, but Vitamin D would not profit the company

Note: The trial is comparing the product against a placebo, not against vitamin D

**OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment for Symptomatic COVID-19 Outpatients Yahoo Finance Aug 30. 2021

Vitamin D Life* Calcidiol ** Time-release form of active vitamin D granted a patent for chronic kidney disease – July 2014

• Modified release active Vitamin D (calcifediol ) for those with poor Kidney function (USD 10,000 per year) – April 2015

• Calcifediol (Calcidiol) is far less cost-effective and available than Vitamin D – RCT June 2021

• Response to weekly Calcifediol in 4 months - RCT Aug 2022

• Weekly response to semi-activated vitamin D slightly better than standard – RCT Nov 2019** Other__

• Vitamin D and COVID, review of evidence, loading dose if less than 50 ng - Masterjohn Sept 2021

COVID-19 treated by Vitamin D - studies, reports, videos

• {include}

Intervention and virus studies:

{category}